An Open-Label Study to Assess the Safety & Efficacy of Leniolisib in Japanese Patients With APDS

NCT06249997 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

3

Enrollment

INDUSTRY

Sponsor class

Conditions

APDS Gene Mutation

Interventions

DRUG: Leniolisib

Sponsor

Pharming Technologies B.V.

Collaborators

[object Object]
[object Object]
[object Object]